SILVER SPRING, MARYLAND (March 6, 2019) — The US Food and Drug Administration today approved Spravato (esketamine) nasal-spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried other antidepressant medicines but have not benefited from them (treatment-resistant depression).
Subscribe & Listen to Reader Podcasts
On Stands Now
Tagged Content
Two Ways to Subscribe
1. Subscribe to free weekly e-mail content updates.
You'll get both the current official narrative challenge and What's Happenin' in the Quad Cities.
(Did you know we publish a new Real Astrology and RCR Crossword every week?)
2. Get 12 monthly issues mailed first class for $48
Get the printed Reader edition mailed to you (or anyone you want) first-class for 12 months for $48.
$24 goes to postage and handling, $24 goes to keeping the doors open!